Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal triamcinolone versus aflibercept for diabetic macular edema
IRCT20251031067835N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Nov 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in diabetic macular edema (DME) comparing Intravitreal triamcinolone acetonide with Intravitreal aflibercept (2 arms). Started Nov 2025; status: completed.
02
Drugs
triamcinolone acetonideaflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on IRCT20251031067835N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251031067835N1.